Kingworld Medicines Group Limited disclosed that its wholly-owned subsidiary, Kingworld Medicine (BVI), has entered into a memorandum of understanding (MOU) with an intended vendor and guarantors regarding a proposed acquisition. The transaction, if completed, would allow the Group to expand its presence in Hong Kong’s pharmaceutical sector, acquire manufacturing assets including landed property, and strengthen its domestic and international business development through enhanced product distribution and operational scale. As of the date of the announcement, no legally binding agreement related to the acquisition has been signed, except for certain provisions concerning the deposit, due diligence, exclusivity, confidentiality, and governing law and jurisdiction under the MOU. Further updates will be provided as appropriate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kingworld Medicines Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260122-11999124), on January 22, 2026, and is solely responsible for the information contained therein.